French retail giant Carrefour supermarket in Saint-Herblain, outside Nantes. Getty Images
Who remembers today that back in 2017, Bruno Le Maire ran for the presidential nomination in his conservative party’s primary on a 1,000-page platform advocating sweeping free-market reforms and the end of state meddling in the economy?
Three years on, Le Maire, now the French economy and finance minister and one of the most prominent members of President Emmanuel Macron’s government, is proving one of the most interventionist economy ministers of later years. And he has shown a particular dislike for the acquisitions of French companies by foreign competitors.
Order Reprints Print Article
China is facing the worst resurgence of the coronavirus since it quashed nearly all of its cases months ago, adding pressure to the rollout of vaccines to its vast population.
Amid this pressure is recent news from Brazil that a Chinese-developed vaccine showed significantly lower efficacy rate in very mild cases compared to its global peers.
China.
Close
China’s Coronavirus Outbreak Collides With Confusion Over Vaccine Efficacy
China is facing the worst resurgence of the coronavirus since it quashed nearly all of its cases months ago, adding pressure to the rollout of vaccines to its vast population.
By Jack Denton Order Reprints Print Article
The owner of retail giant Primark estimates that the loss of sales from store closures caused by the Covid-19 pandemic will cost the company £1.05 billion ($1.43 billion), as it moves to expand further into the U.S. market. Primark operates 11 stores in the U.S., mostly on the East Coast.
Shares in Associated British Foods, which owns Primark, rose 1% in London trading, as it reported results for its grocery, sugar, agriculture, and ingredients businesses that outpaced expectations.
The.
Close
Store Closures Due to Covid-19 Will Cost This Retailer $1.4 Billion. It Still Won’t Move Online.
New data on early-stage trials of
Johnson & Johnson’s Covid-19 vaccine are giving experts increased confidence that the vaccine will work as they await results of a large Phase 3 trial expected in the coming weeks.
The trial data, published Wednesday by the New England Journal of Medicine, offered an expanded and updated account of a paper posted weeks ago on a so-called preprint server. The paper showed that 90% or more of participants developed neutralizing antibodies against the virus that causes Covid-19 within 29 days after injection with the Johnson & Johnson vaccine, and that the neutralizing antibodies remained 71 days after injection.
Shares of Johnson & Johnson were up 1.8% in premarket trading on Thursday.